Trilostane API
A Clinically Proven Active Pharmaceutical Ingredient for Canine Cushing's Disease
Product Overview
Trilostane API is an active pharmaceutical ingredient widely used in veterinary medicine, primarily for the treatment of canine Cushing's disease (hyperadrenocorticism) . It works by inhibiting cortisol synthesis in the adrenal glands, helping restore hormonal balance and significantly improving the quality of life in affected dogs.
Product Name: Trilostane API
CAS Number: 13647-35-3
Quality Standard: In-House / IP / EP / BP
Category: Veterinary Active Pharmaceutical Ingredient (API)
Mechanism of Action
The primary mechanism of Trilostane is the inhibition of adrenal steroid synthesis . It blocks the enzyme responsible for cortisol production, resulting in controlled and reduced cortisol levels. This targeted action enables it to:
▸ Reduce excessive cortisol production in the adrenal glands
▸ Restore normal hormonal balance and metabolic function
▸ Alleviate clinical signs of Cushing's disease
▸ Maintain essential adrenal function while controlling overproduction
Veterinary Applications of Trilostane
1. Treatment of Canine Cushing's Disease
Trilostane is clinically proven for managing Cushing's syndrome in dogs - a condition caused by excessive production of cortisol. Elevated cortisol levels disrupt normal metabolic processes and lead to symptoms such as:
▸Excessive thirst and urination
▸ Increased appetite and weight gain
▸ Lethargy, hair loss, and weakened immunity
A high percentage of dogs treated with Trilostane show noticeable improvement in symptoms, including better energy levels, improved coat condition, and normalized drinking and eating behaviors.
2. Inhibition of Adrenal Steroid Synthesis
By selectively blocking the enzyme responsible for cortisol production, Trilostane provides a targeted and controlled approach to adrenal management. This makes it one of the most trusted therapeutic options for:
▸ Long-term management of canine Cushing's disease
▸ Controlled reduction of adrenal hormone overproduction
▸ Preservation of essential adrenal functions during treatment
3. Safety and Long-Term Use
Trilostane is considered safe and well tolerated when administered according to veterinary guidance. It has been proven suitable for long-term use , making it an effective ongoing treatment. Key safety considerations include:
▸ Minimal side effects manageable with dosage adjustment
▸ Regular hormone level monitoring recommended for optimal dosing
▸ Sustained therapeutic results with proper veterinary supervision
Benefits of Trilostane API
▸ Effective control of cortisol overproduction
▸ Proven treatment for canine Cushing's disease
▸ Improves energy, appetite regulation, and coat condition
▸ Suitable for long-term veterinary therapy
▸ High safety profile when used correctly
▸ Enhances overall health and quality of life in dogs
Our Manufacturing Strengths
Complete Manufacturing System
Our manufacturing facility covers a total area of 2,523 m² , including 365 m² of Class D clean areas . The site is designed and operated in full compliance with GMP standards to ensure consistent API quality and safety at every production stage.
Strict Quality Control
We implement strict quality control procedures at every stage of production, including:
▸ Raw material verification and incoming inspection
▸ Environmental monitoring throughout production
▸ Batch testing to guarantee product reliability and safety
Excellent Customer Service
Customer satisfaction is our ongoing commitment. We work closely with our clients to understand their needs and provide comprehensive technical, regulatory, and commercial support tailored to each partnership.
Frequently Asked Questions
Q1: What application fields do your products cover?
Our products are widely used in reproduction, endocrinology, and gynecology for both human and veterinary applications.
Q2: Can customers visit your factory for quality audits?
Yes. Customers are welcome to conduct on-site audits when required. Please contact us in advance to schedule a visit - we are always ready to assist.
Conclusion
Trilostane API Pharmaceutical Grade (CAS 13647-35-3) is a highly effective and trusted treatment for canine Cushing's disease. Its targeted inhibition of adrenal cortisol synthesis, proven long-term safety profile, and consistent clinical results make it an indispensable API in modern veterinary endocrinology. When used responsibly under veterinary supervision, Trilostane delivers meaningful improvements in animal health, comfort, and quality of life.
Hot Tags: trilostane api, China trilostane api manufacturers, suppliers, factory, small molecule compounds in veterinary drug discovery, small molecular products for veterinary drug discovery, Clorhidrato de Dexmedetomidina, Small Molecular Compounds for Veterinary, veterinary small molecular compounds for new drug development, Mavacoxib
